60 DEGREES PHARMA INC (SXTP) Stock News

USA - NASDAQ:SXTP - US83006G4010 - Common Stock

1.36 USD

-0.02 (-1.45%)

Last: 10/31/2025, 8:15:25 PM

1.34 USD

-0.02 (-1.47%)

After Hours: 10/31/2025, 8:15:25 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

SXTP Latest News, Press Relases and Analysis

All

Press Releases

2 days ago - By: ACCESS Newswire - Mentions: NDTP

60 Degrees Pharmaceuticals and NDT Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

18 days ago - By: Sixty Degrees Pharmaceuticals

60 Degrees Pharmaceuticals Announces No Detection of Babesia Infection in First Patient Following Treatment with Tafenoquine in Relapsing Babesiosis Study

24 days ago - By: Sixty Degrees Pharmaceuticals

60 Degrees Pharmaceuticals Unveils Name of Chronic Babesiosis Clinical Trial: B-FREE Chronic Babesiosis Study

a month ago - By: ACCESS Newswire

Join 60 Degrees Pharmaceuticals' Exclusive Live Investor Webinar and Q&A Session on October 22

a month ago - By: ACCESS Newswire - Mentions: ENLV

Enlivex Therapeutics and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

2 months ago - By: Benzinga - Mentions: WTFC BWA CHE MTB ...

Alphabet To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Wednesday

2 months ago - By: Sixty Degrees Pharmaceuticals

60 Degrees Pharmaceuticals Live Webcast Link and New Date for Presentation at H.C. Wainwright 27th Annual Global Investment Conference

2 months ago - By: Sixty Degrees Pharmaceuticals

60 Degrees Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference

3 months ago - By: Sixty Degrees Pharmaceuticals

60 Degrees Pharmaceuticals Selects Icahn School of Medicine at Mount Sinai as Central Clinical Trial Site for Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis

3 months ago - By: Sixty Degrees Pharmaceuticals

60 Degrees Pharmaceuticals Announces Second Quarter 2025 Results

3 months ago - By: ACCESS Newswire - Mentions: APVO

Aptevo Therapeutics and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

3 months ago - By: Zacks Investment Research - Mentions: ARDX

Ardelyx (ARDX) Reports Q2 Loss, Tops Revenue Estimates

4 months ago - By: Sixty Degrees Pharmaceuticals

60 Degrees Pharmaceuticals and Tulane University Sign Research Agreement to Study Tafenoquine Against Lyme and Bartonella Bacteria

4 months ago - By: Sixty Degrees Pharmaceuticals

60 Degrees Pharmaceuticals Announces Closing of up to $10 Million Public Offering

4 months ago - By: Benzinga - Mentions: CYCC SLP SSII LIXT ...

12 Health Care Stocks Moving In Tuesday's Intraday Session

4 months ago - By: Sixty Degrees Pharmaceuticals

60 Degrees Pharmaceuticals Announces Pricing of Up to $10 Million Public Offering

4 months ago - By: Sixty Degrees Pharmaceuticals

60 Degrees Pharmaceuticals Defines Potential Human Babesiosis Market Size for ARAKODA® (tafenoquine): Annual Max TAM, Sales of $245 Million; Cumulative through Patent Expiration, $1.1 Billion

4 months ago - By: Sixty Degrees Pharmaceuticals

60 Degrees Pharmaceuticals to Submit MUMS (Minor Use/Minor Species) Designation Request to FDA for Tafenoquine for Acute Canine Babesiosis in 2025

5 months ago - By: ACCESS Newswire - Mentions: LBSR

60 Degrees Pharmaceuticals and Liberty Star Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

5 months ago - By: Sixty Degrees Pharmaceuticals

60 Degrees Pharmaceuticals Expands Options for Malaria Prevention with Introduction of ARAKODA® (tafenoquine) 8-Count Bottle Format

5 months ago - By: Sixty Degrees Pharmaceuticals

Babesiosis Incidence in U.S. 10x Higher Than CDC Estimates, According to Insurance Claims Study Commissioned by 60 Degrees Pharmaceuticals

6 months ago - By: Sixty Degrees Pharmaceuticals

60 Degrees Pharmaceuticals Announces First Quarter 2025 Results

6 months ago - By: Zacks Investment Research - Mentions: HROW

Harrow (HROW) Reports Q1 Loss, Lags Revenue Estimates

6 months ago - By: Sixty Degrees Pharmaceuticals

Babesiosis Disease Burden in United States is Substantially Higher Than Official Estimates, According to Preliminary Results of 60 Degrees Pharma Survey

7 months ago - By: Yahoo Finance

Why 60 Degrees Pharmaceuticals, Inc. (SXTP) Went Down On Thursday?

7 months ago - By: Sixty Degrees Pharmaceuticals

Geoff Dow, PhD, Infectious Disease Product Development Expert, to Discuss Babesiosis at Healing Lyme Summit, April 15-21